
简介:
- 作者: Feiyu Zhao, Tao Zhang, Xiaodi Sun, Xiyun Zhang, Letong Chen, Hejun Wang, Jinze Li, Peng Fan, Liangxue Lai,Tingting Sui and Zhanjun Li
- 杂志: Nat Commun
- Doi: https://www.doi.org/10.1038/s41467-023-41320-8
- 出版日期: 2023 Sep 8
论文中使用的产品/服务
Quotation shows PackGene:AAV injection PackGene Biotech (China) created the AAV-mini-RfxCas13d-Pcsk9-crRNA2 expression cassettes and produced the viruses (https://www.packgene.cn/about-us/). An AAV injection assay was performed as previously described44. Production of AAV8-RfxCas13d vectors was performed by PackGene Biotech (China).The AAV-mini-RfxCas13d-Pcsk9-crRNA2 titer was 2 × 1012 genome copies (GCs)/mL.
Research Field:Liver, blood
AAV Serotype:AAV8
Targeted organ:Liver, blood
Animal or cell line strain:mouse
摘要
The small size of the Cas nuclease fused with various effector domains enables a broad range of function. Although there are several ways of reducing the size of the Cas nuclease complex, no efficient or generalizable method has been demonstrated to achieve protein miniaturization. In this study, we establish an Interaction, Dynamics and Conservation (IDC) strategy for protein miniaturization and generate five compact variants of Cas13 with full RNA binding and cleavage activity comparable the wild-type enzymes based on a combination of IDC strategy and AlphaFold2. In addition, we construct an RNA base editor, mini-Vx, and a single AAV (adeno-associated virus) carrying a mini-RfxCas13d and crRNA expression cassette, which individually shows efficient conversion rate and RNA-knockdown activity. In summary, these findings highlight a feasible strategy for generating downsized CRISPR/Cas13 systems based on structure predicted by AlphaFold2, enabling targeted degradation of RNAs and RNA editing for basic research and therapeutic applications.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
